Abstract
In The Lancet Infectious Diseases, Emily E Coates and colleagues1 describe a phase 1 human trial of a trivalent vaccine of western, eastern, and Venezuelan equine encephalitis (WEVEE) comprising a 1:1:1 mixture of virus-like particles (VLPs) generated in HEK293 cells. The VLPs comprised the self-assembled structural proteins of western equine encephalitis virus (WEEV), eastern equine encephalitis virus (EEEV), and Venezuelan equine encephalitis virus (VEEV). The results show among other findings that at 24 weeks after two intramuscular vaccinations of 60 μg total dose of alum-adjuvanted vaccine given 8 weeks apart, five (100%) of five volunteers developed neutralising antibody titres to all three viruses that at a dilution of at least one in ten reduced virus plaques by 80% (as measured with the plaque reduction neutralisation test).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
